Core Viewpoint - The company, Haohai Biological Technology (昊海生科), is facing significant challenges due to insider trading investigations involving its major shareholder, Jiang Wei, and a sharp decline in revenue growth and profitability in its core business segments, particularly in the medical aesthetics sector [1][2]. Financial Performance - In 2024, Haohai's revenue growth plummeted to 1.64%, with net profit only slightly increasing by 1.04%. In Q1 2025, both revenue and net profit further declined, with revenue decreasing by 4.25% and net profit dropping by 7.41% [1]. - The company announced a cash dividend of 231 million yuan in 2024, which accounted for 54.92% of its net profit, raising concerns about its financial sustainability amid declining performance [1][8]. Business Segments - The medical aesthetics segment, particularly the hyaluronic acid business, saw revenue of 742 million yuan in 2024, a significant slowdown from a 95.54% growth in 2023 to just 23.23% [5][6]. - The ophthalmology segment, as the second-largest supplier of artificial lenses in China, experienced a revenue decline of 7.60% in 2024, with specific product lines like artificial lenses and ophthalmic viscoelastic devices seeing drops of 14.06% and 19.53%, respectively [7][8]. Market Challenges - The hyaluronic acid market is facing intense competition, with over 400 brands and more than 50 approved Class III medical devices, leading to market saturation [5][6]. - The rise of alternative materials, such as collagen-based products, is impacting the demand for hyaluronic acid, with the retail market for collagen products projected to reach 173.8 billion yuan by 2027 [6]. - Regulatory changes have also affected the radiofrequency and laser equipment business, with new classifications requiring re-approval, leading to a 6.97% revenue decline in this segment [6]. Governance and Control - Jiang Wei and his wife, You Jie, control approximately 45.82% of the company’s shares, allowing them significant influence over corporate decisions despite Jiang not holding an official position [5][1]. - Concerns about corporate governance have been heightened due to the ongoing investigation into Jiang Wei, which may reflect deeper issues within the company's management practices [1][2].

Core Viewpoint - The recent investigation of Jiang Wei, a major shareholder of Haohai Biological Technology, by the China Securities Regulatory Commission for suspected insider trading is not expected to significantly impact the company's operations or stock performance [1][2]. Company Overview - Haohai Biological Technology is recognized for its "medical aesthetics + ophthalmology" business model, with a focus on high-margin products such as artificial lenses and medical-grade hyaluronic acid [2][3]. - The company is the first biopharmaceutical firm listed on both the Hong Kong Stock Exchange and the Shanghai Stock Exchange's Sci-Tech Innovation Board [2]. Financial Performance - Revenue has shown consistent growth from 1.3 billion yuan in 2020 to 2.6 billion yuan in 2024, while net profit increased from 200 million yuan to 400 million yuan during the same period, despite a significant drop in 2022 [2][3]. - In 2024, the company reported revenue of 2.698 billion yuan, a year-on-year increase of 1.64%, and a net profit of 420 million yuan, up 1.04% [3]. Market Challenges - The medical aesthetics and ophthalmology sectors are facing increased competition and price reductions due to national procurement policies, leading to stagnation in revenue growth for 2024 [3]. - The medical aesthetics segment has shown signs of growth fatigue, with revenues from medical beauty and wound care products increasing from 460 million yuan in 2021 to 1.2 billion yuan in 2024, but growth rates are declining [3]. Product Development - In July 2024, Haohai Biological Technology received approval for its fourth-generation hyaluronic acid product, Hai Mei Yue Bai, aimed at treating moderate to severe nasolabial folds, positioning it as a potential growth driver in the high-end medical aesthetics market [4]. - The product is priced at 13,800 yuan for 1ml and 19,800 yuan for 2ml, indicating a premium positioning [4]. Recent Performance - In the first quarter of 2024, the company experienced a decline in both revenue and net profit, with revenue at 619 million yuan, down 4.25%, and net profit at approximately 90.31 million yuan, down 7.41% [4].

Core Viewpoint - The company, Haohai Biological Technology (688366.SH), is facing scrutiny as its controlling shareholder, Jiang Wei, has been notified of an investigation by the China Securities Regulatory Commission for suspected insider trading, which has raised concerns among investors [1][3]. Company Overview - Haohai Biological Technology is a well-known producer of hyaluronic acid in China, with its founders Jiang Wei and You Jie being the controlling shareholders [1]. - The company has been listed on both the Hong Kong Stock Exchange and the Shanghai Stock Exchange, making it the first biopharmaceutical company to achieve dual listing on the "H+ Sci-Tech Innovation Board" [1]. Financial Performance - In 2024, Haohai Biological Technology reported total revenue of 2.698 billion yuan, a year-on-year increase of 1.64%, while the net profit attributable to shareholders decreased by 1.12% to 379 million yuan [2]. - The overall gross margin slightly declined from 70.46% to 69.89% in 2024, attributed to a significant drop in sales prices of certain products due to new rounds of national or provincial procurement [2]. - The company's revenue from the ophthalmology sector saw a notable decline, with the cataract product line generating 420.73 million yuan, down 15.33% year-on-year [2]. Market Reaction - Following the announcement of Jiang Wei's investigation, Haohai Biological Technology's stock experienced a decline of 4.81% in early trading on May 8, closing down 0.70% at 52.80 yuan, with trading volume significantly increasing compared to the previous day [3].

Investment Rating - The report maintains a "Buy" rating for the company [4][6]. Core Views - The company reported a total revenue of 621 million yuan in Q1 2025, a decrease of 4.44% year-on-year, with a net profit attributable to the parent company of 90 million yuan, down 7.41% [1]. - The ophthalmology business faced challenges due to price declines from centralized procurement, while the medical aesthetics sector continued to experience weak terminal consumption [2]. - The company is focused on R&D and innovation, with new products steadily advancing, including approvals for new intraocular lenses and the launch of the fourth-generation hyaluronic acid product "Hai Mei Yue Bai" [2]. - The gross profit margin slightly improved to 69.52% in Q1 2025, attributed to an increase in the proportion of high-margin medical aesthetics products [3]. - The company expects revenue growth to reach 3.103 billion yuan in 2025, with net profit projected at 489 million yuan, reflecting a compound annual growth rate of 16.42% from 2024 to 2025 [4][5]. Summary by Sections Financial Performance - In Q1 2025, the company achieved a gross profit margin of 69.52%, with a net profit margin of 14.60% [3]. - The company reported a stable expense ratio of 51.79%, with sales expenses increasing slightly to 31.35% [3]. - The operating cash flow for Q1 2025 was 86 million yuan, indicating healthy cash flow management [3]. Product Development - The company is advancing its product pipeline, including new medical aesthetics products and intraocular lenses, which are expected to enhance market share [2]. - The innovative "Hai Mei Yue Bai" product is anticipated to address long-standing consumer issues related to hyaluronic acid retention [2]. Market Outlook - The report forecasts revenue growth for the company from 3.103 billion yuan in 2025 to 3.934 billion yuan in 2027, with a corresponding increase in net profit [4][5]. - The company is positioned to benefit from a recovery in the ophthalmology sector as product pipelines expand and centralized procurement impacts stabilize [4].

文 ｜ 裘翔 刘春彤 杨家骥 高玉森 连一席 遥远 在彻底取消所有对华单边关税措施前，中美贸易谈判可能进展有限；国内的政策是托底和应对式的，4月只是第一波以试验和预防为特征 的政策；筹码出清相对彻底且对业绩不敏感的主题阶段性占优；市场整体情绪位置不算低，科技板块相对医药和消费更接近冰点，对风偏 回升更敏感。配置上，5月关注新技术和产业题材轮动、海外科技映射链修复以及服务业扩内需政策落地。 在彻底取消所有对华单边关税措施前， 中美贸易谈判可能进展有限 近期特朗普针对关税问题表态持续反复，美股市场反应较为敏感。但我们认为国内投资者不需要花精力关心这些高频变化，特朗普试图灵活 利用关税武器来制造谈判筹码，而中国商务部新闻发言人何亚东表示"如果美方真的想解决问题，就应该正视国际社会和国内各方理性声音， 彻底取消所有对华单边关税措施，通过平等对话，找到解决分歧的办法"。我们建议还是关注特朗普未来一年面临的两大约束，一是7~8月需 要推进债务上限谈判和减税法案通过，二是明年中期选举。尽管目前特朗普的民调支持率已经开始明显下降，但这属于每个美国总统百日新 政后正常的回落，而特朗普两次任期的民调本身就比其他美国总统偏低，目前 ...

"与第三方买家合作将博士伦私有化，是公司为从博士康完全分离而探索的几种方案之一，"博士伦在声明中表示。" 在与潜在买家进行接洽后，这一过程已经完 成，目前不会促成任何交易 。" " 完全分离仍然是我们的目标 。 博士伦将继续作为独立实体运营，并执行其战略和商业计划 。该公司在10月30日上调了2024年的收入预期，并将于2月19日报告 2024年第四季度和全年业绩，同时还将提供2025财年的预期。" 想象一下，一个企业拥有172年的历史，这是怎样的一个存在？当你走进它的总部时，可能都不自觉向它的创始人致敬。它就是 成立于1853年的博士伦 ，2022年于 纽交所和多伦多证券交易所同步上市，与爱尔康、强生、蔡司、库博被并称为眼科五巨头， 规模仅次于爱尔康，排名世界第二 。 近日， 博士伦（Bausch + Lomb）宣布，在与潜在的买家进行了讨论之后，目前没有计划立即出售公司 。 去年10月， 位列全球最大私募股权投资公司的 黑石集团（Blackstone）和德太投资（TPG Capital）正在考虑 联手收购博士伦 。 据英国《金融时报》报道，早在 2022年上市之前，博士伦就收到了私募股权公司的兴趣要约。 ...